Vasilisa Sazonov

Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada

Anselm K. Gitt, Heinz Drexel, J. Feely et al. · European Journal of Preventive Cardiology · 2011 · 163 citations · Full text

Pharmacy, Cardiology, Pharmacotherapy +11

Low-density lipoprotein cholesterol in a global cohort of 57,885 statin-treated patients

Anselm K. Gitt, Dominik Lautsch, Jean Ferrières et al. · Atherosclerosis · 2016 · 110 citations

Life Sciences, Health Sciences, Clinical Epidemiology +11

Treatment persistence among patients with immune-mediated rheumatic disease newly treated with subcutaneous TNF-alpha inhibitors and costs associated with non-persistence

Johan Dalén, Axel Svedbom, Christopher M. Black et al. · Rheumatology International · 2016 · 63 citations

Life Sciences, Immunology, Internal Medicine +14

Reasons for not initiating osteoporosis therapy among a managed care population

Ankita Modi, Jingbo Yu, Susan K. Brenneman et al. · Patient Preference and Adherence · 2015 · 39 citations · Full text

Medicine, Orthopedic Surgery, Bone Metabolism +15

Frequency of Obtaining National Cholesterol Education Program Adult Treatment Panel III Goals for All Major Serum Lipoproteins After Initiation of Lipid Altering Therapy††Conflicts of interest: Drs. Nichols and Brown are employees of Kaiser Permanente Northwest. Drs. Ambegaonkar and Sazonov are employees of Merck & Company, Inc. Drs. Nichols and Brown have received research support from Amgen, Inc., Thousand Oaks, California; Novo Nordisk A/S, Bagsværd, Denmark; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; Takeda Pharmaceuticals North America, Inc., Deerfield, Illinois; and GlaxoSmithKline, Inc., London, United Kingdom.

Gregory A. Nichols, Baishali Ambegaonkar, Vasilisa Sazonov et al. · The American Journal of Cardiology · 2009 · 31 citations

Pharmacy, Pharmacotherapy, Cardiovascular Pharmacotherapy +12